期刊文献+

壳聚糖接枝聚赖氨酸苄酯负载紫杉醇纳米胶束的制备及性能研究

Preparation and Properties of Chitosan Grafted Poly (Lysine Benzyl Ester) Loaded Paclitaxel Micelle
下载PDF
导出
摘要 [目的]:利用自主装法制备载紫杉醇纳米胶束。[方法]:以壳聚糖接枝聚赖氨酸苄酯作为载体负载紫杉醇,通过自主装的方法制备载药胶束,通过体外释放实验考察载药胶束中紫杉醇的释放规律,通过Zeta电位粒径测定仪测定载药胶束的粒径。[结果]:通过自主装的方法能够顺利制备得到紫杉醇载药胶束,体外释放实验表明紫杉醇在纳米胶束中的释放包含了一个快速释放及一个缓慢释放的过程。载药胶束的粒径范围在40-120nm之间。 [Purpose]:Paclitaxel loaded micelles were prepared by self loading method.[Methods]:Paclitaxel-loaded micelles were prepared by self-loading method with chitosan grafted poly(L-L-benzyl ester)as carrier.The release of paclitaxel in the drug-loaded micelles was investigated in vitro.The particle size of the drug-loaded micelles was determined by Zeta potential particle size analyzer.[Results]:Paclitaxel-loaded micelles were successfully prepared by self-loading method.In vitro release experiments showed that paclitaxel release in micelles included a rapid release and a slow release process.The size range of drug loaded micelles is between40-120nm.
作者 余卓璇 林坚涛 Yu Zhuoxuan;Lin Jiantao(Guangdong Medical University,Dongguan 523808,Guangdong,China)
机构地区 广东医科大学
出处 《四川化工》 CAS 2018年第6期8-10,共3页 Sichuan Chemical Industry
关键词 壳聚糖 紫杉醇 纳米胶束 chitosan paclitaxel nano-micelle
  • 相关文献

参考文献3

二级参考文献40

  • 1施水萍,冯年平,武培怡.聚酯型高分子纳米载药系统研究进展[J].中国现代应用药学,2005,22(3):205-209. 被引量:7
  • 2Liu JS, Kuo SR, Mc Hugh MM, et al. Adozelesin triggers DNA damage response pathways and SV40 DNA replication through replication protein A inactivation [J ]. J Biol Chem, 2000,275 (2) : 1391-1397.
  • 3Awada A, Punt CJ, Piccart MJ , et al. Phase I study of Carzelesin(U-80,244) given (4-weekly) by intravenous bolus schedule [J]. Br J Cancer, 1999,79 (9-10):1454-1461.
  • 4Armand JP, Seymour L, Evans TR. Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines, preliminary results of phase I clinical trials[J] .Eur J Cancer,1999,35 Suppl 1:S14-18.
  • 5Igarashi H, Ito T, Ogoshi K, et al. Successful arterial administration therapy of SMANCS for liver metastasis of malignant insulinoma[ J]. Pancreas, 1999, 19 (2): 207-210.
  • 6Van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometeial cancer after tomoxifen of breast cancer[J]. Lancet, 1994,343(8895) :448.
  • 7Uchida N, Takeda Y, Kasai H, et al. Antitumor efficacy of nedaplation, a novel platinum complex, with cyclophosphamide in rnurine and human tumor model[ J ].Anticancer Res, 1998,18(5A) :3375-3379.
  • 8Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity [J]. Ann Oncol,2002,13(12) : 1841-1851.
  • 9Morris R, Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancel[J]. Oncologist, 2002,7(Soppl 5) :29-35.
  • 10Holm-Hansen SV, Kamby C, Dombemowsky P. Herceptin(traszumab) :a new exciting theraprutic principlein breast cancer[J]. Ugeskr Laeger,2000,162(2) : 189-190.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部